Glycemic gap and the outcome of diabetic patients presenting with acute coronary syndrome

Yehia Mostafa Ghanem1, Mona Wagdy Ayad2, Azza Abdel Kareem1, Maged Osama Guirguis3, Asmaa Mohamed Alkafafy3 and Mai Hesham Badrah1*

Abstract
Background: Acute hyperglycemia is a common finding in both diabetic and non-diabetic patients with acute coronary syndrome (ACS) who present to the emergency department (ED). The prognostic role of hyperglycemia in diabetic patients with ACS remains controversial at least on the short-term basis. The aim of the present study was to find the relation between the glycemic gap and clinical outcome in diabetic patients with ACS.

Methods: The study included 100 diabetic patients with ACS to who were prospectively followed during their hospital stay. Admission blood glucose was measured and glycemic gap was calculated.

Results: In diabetic patients suffering ACS, there was a significant relation between the glycemic gap value, occurrence of major adverse cardiovascular events (MACE) and length of hospital stay.

Conclusion: Glycemic gap is a better marker than admission blood glucose alone in diabetic patients presenting with ACS. This study added the optimal cut-off value for this important biomarker.

Keywords: Hyperglycemia, Glycemic gap, Diabetes, Acute coronary syndrome, MACE

Background
Acute hyperglycemia is a common finding in patients who present to the emergency department (ED) suffering acute coronary syndrome (ACS) in both diabetic and non-diabetic patients. The prognostic role of hyperglycemia in non-diabetic patients with (ACS) may be well established, compared to diabetic patients in whom it remains controversial at least on the short-term basis [1, 2]. In diabetic patients, hyperglycemia is the cardinal feature which may be noticed regardless of a stressful event due to poor glycemic control [3].

The chronic effects of hyperglycemia are associated with long-term dysfunction, damage, and failure of various organs, especially the nerves, kidneys, eyes, heart, and blood vessels [4].

Stress hyperglycemia is defined as a transient increase in blood glucose concentration during acute illness. It represents two distinct populations of patients; those with undiagnosed diabetes or impaired glucose tolerance, and those who develop hyperglycemia as the result of hormonal surges in response to severe stress. Evidence shows that stress hyperglycemia involves increased insulin resistance in tissues and organs, increased gluconeogenesis, decreased glycogenolysis, and increased lipolysis. Elevated oxidative stress and increased serum levels of pro-inflammatory cytokines, cortisol, and glucagon promote these activities [5–7].

In patients with ACS, the concomitant occurrence of hyperglycemia enhances the risk of morbidity and mortality whether or not the patient had a prior diagnosis of diabetes. Stress hyperglycemia shares many properties...
with hyperglycemia associated with type 2 diabetes, including increased oxidative stress, inflammation, and activation of stress-responsive kinases. Infarcts are usually larger in patients with stress-related hyperglycemia. Severe infarction and increased sensitivity to ischemia-reperfusion injury are predictors of poor prognosis in ACS patients with stress hyperglycemia. Evidence from clinical and preclinical studies suggests that insulin resistance and glucose homeostasis play key roles by predisposing hyperglycemic myocardial tissue to injury during ischemia and reperfusion [8, 9].

**Methods**

**Study population**
In this study, a total of 113 diabetic patients aged between 40 and 81 years were recruited from emergency department at Alexandria Main University Hospital, Egypt. Thirteen patients were excluded for acute coronary syndrome mimics, (seven diagnosed as pneumonia, three diagnosed as pericarditis, two diagnosed as pneumothorax, and one diagnosed as aortic dissection). Statistics were done on 100 patients who met the inclusion criteria.

Patients younger than 18 years, pregnant females, patients presented with hemodynamic instability, and those with hemoglobinopathies were excluded from this study. All the participants included in the study were informed about the nature of the study, and their consent on participating voluntarily was obtained. The study was approved by the Ethical Committee of the Faculty of Medicine, Alexandria University.

After giving their consent, all study participants were subjected to full medical history assessment including demographic details, characters and duration of the chest pain, risk factors for ACS, and complete physical examination was done for all patients.

**Biochemical analysis**
Blood samples were collected from all patients for blood gases analysis and cardiac biomarkers of ischemia, i.e., CK-MB and high sensitivity Troponin. Glycated hemoglobin (HbA1c) percentage was determined using high performance liquid chromatography (HPLC) method. Random blood glucose was measured by finger stick sample for capillary blood glucose measurement which was subsequently confirmed by serum blood glucose level in the laboratory.

A 12-lead ECG was done for all patients within 10 min of presentation and all patients had a chest radiograph to exclude the risk of ACS mimics, e.g., aortic dissection, pneumothorax, and pneumonia.

The following formula was used to convert HbA1c levels to the estimated A1c-Derived Average glucose (ADAG) levels: $28.7 \times \text{HbA1c} - 46.7$ [10]. The glycemic gap, which shows changes in blood glucose levels during the acute event, was calculated from the glucose level measured at ED minus the ADAG level [11].

The glycemic gap had been correlated with the patients’ outcome which was assessed by the complications that occurred to the patient during his duration of stay and the length of that stay. Complications during hospitalization were considered in any patient that witnessed a sudden cardiac arrest, life threatening arrhythmias or acute pulmonary edema [12–14].

**Statistical analysis**
Collected data were expressed as mean and standard deviation and were analyzed using the two-tailed Student’s t test. Categorical data are expressed as frequencies (%) and were evaluated using the chi-square test or Fisher’s exact test. A one-way analysis of variance was used to assess the significance of various characteristics, laboratory data, and adverse outcomes. A post-hoc analysis was performed using the Bonferroni test. A receiver–operator characteristic curve (ROC) curve was plotted to analyze the discriminative power of the prediction tools, and the area under the ROC (AUROC) and the corresponding 95% confidence intervals (CI) were calculated.

Univariate and multivariate Cox hazard regression analyses were performed to identify the risk factors associated with MACEs. Variables with a $p < 0.05$ in the univariate analysis were entered into the multivariate Cox hazard regression analysis. The correlation between glycemic gap and continuous variables was evaluated by the Pearson product-moment correlation. The correlation between the glycemic gap and ordinal variables was evaluated by the Spearman’s rank-order correlation. The data were analyzed using Statistical Package for the Social Sciences statistical software (SPSS, Inc., Chicago, IL, USA), version 20.0 and differences with $p$ values < 0.05 were considered statistically significant.

**Results**
This study was conducted on 100 diabetic patients who presented to ED with ACS. The study included 74 males and 26 females with a mean age of 60.33 ± 10.06 years.

Thirty six patients witnessed major adverse cardiac event (MACE) during their hospital stay where 6 patients suffered cardiac arrest, 24 patients suffered pulmonary edema, and 13 patients suffered life threatening dysrhythmias; of note, some patients had more than one complication during their hospital stay.

Diabetic patients who suffered MACE had significantly higher glycemic gap compared to patients who did not have MACE ($p < 0.001$) while there was no significant difference between both groups regarding admission
There was a significant positive correlation between the glycemic gap value and the occurrence of MACE (Fig. 1), there was a significant negative correlation between HbA1c level and the occurrence of MACE in diabetic patients suffering ACS (Fig. 2).

Moreover, on performing regression analysis, out of all criteria, there was significant relation between age and MACE occurrence with a $p$ value $< 0.001$. The Cox proportional hazard model revealed that the hazard ratio of the glycemic gap (mg/dL) for MACE was 1.028 (95% CI 1.000–1.005, $p < 0.001$). Therefore it was clear that the glycemic gap and age are independent predictors of MACE occurrence in diabetic patients with ACS. The results of univariate and multivariate analyses are shown in Table 2.

The ROC curve analysis for the glycemic gap value to predict MACE in diabetic patients suffering ACS, it was found that the optimal cut-off value of the glycemic gap was 55 mg/dl with maximum AUROC of 0.796 (95% CI = 0.702–0.891) (sensitivity 86.11% and specificity 56.25%). Moreover, glycemic gap was more specific rather than admission RBG level in predicting MACE as shown in Fig. 3 and Table 3.

Moreover, a significant positive correlation was found between glycemic gap value and the length of hospital stay of ACS patients with diabetes; either coronary care unit (CCU), ward stay, or both collectively with $p$ value $< 0.001$. There was also a statistical inverse significant correlation between HbA1c level and the total hospital stay ($p = 0.036$) but there was no statistical significance between admission RBG and the length of hospital stay ($p = 0.064$).

**Discussion**

Cardiac arrest, pulmonary edema and life-threatening dysrhythmia are fatal complications that may occur following ACS. Early identification of patients who are at

### Table 1 Relation between MACE and different glycemic parameters ($n = 100$)

| Variable                  | Overall complication | $p$      |
|---------------------------|----------------------|----------|
|                           | Without MACE ($n = 64$) | MACE ($n = 36$) |   |
| Admission RBG (mg/dl)     | 284.92 ± 56.41       | 286.75 ± 59.17 | 0.879 |
| Glycemic gap value (mg/dl)| 58.49 ± 36.27        | 100.28 ± 43.25 | < 0.001* |

$p$ value for association between different categories

*Statistically significant at $p \leq 0.05$
high risk of developing those complications may help in reducing morbidity and mortality [15]. Numerous studies have shown that hyperglycemia is a commonly encountered issue in critically ill patients in ED and in the critical care settings even in patients without diabetes mellitus [16–20]. A recent analysis of medical records showed that hyperglycemia was present in 38% of adult patients admitted to hospital, of whom 26% had a known history of diabetes, and 12% had no history of diabetes before the admission [19]. In this context, the adverse prognostic impact of hyperglycemia which accompanies ACS was paid considerable attention of the medical societies. It is now well established that acute hyperglycemia that

![Fig. 2](image)

**Table 2** Univariate and multivariate analysis for the parameters affecting MACE

| Univariate | Multivariate |
|------------|-------------|
| p | OR (95% CI) | p | OR (95% CI) |
| Female | 0.761 | 1.154 (0.458–2.904) | 0.528 | 0.691 (0.219–2.180) |
| Age (years) | 0.315 | 0.979 (0.939–1.021) | 0.003* | 1.094 (1.032–1.161) |
| Hypertension | 0.270 | 1.595 (0.695–3.658) | | |
| CCS (chronic coronary syndrome) | 0.549 | 1.320 (0.533–3.270) | | |
| PVD (peripheral vascular disease) | 0.491 | 1.559 (0.440–5.521) | | |
| Dyslipidemia | 0.351 | 1.606 (0.594–4.346) | | |
| Smoking | 0.523 | 0.765 (0.336–1.741) | | |
| STEMI-ACS | 0.258 | 1.667 (0.688–4.040) | | |
| PCI management (stent) | 0.145 | 1.879 (0.804–4.391) | | |
| Glycemic gap value (mg/dl) | < 0.001* | 1.029 (1.014–1.043) | < 0.001* | 1.028 (1.013–1.043) |

*All variables with p < 0.05 was included in the multivariate

*Statistically significant at p ≤ 0.05

*OR odd’s ratio, CI confidence interval
accompanies ACS at presentation is one of the predictors of poor outcomes upon hospital admission and an important prognostic marker for all-cause death in patients with ACS, whether or not they had previously known diabetes mellitus [5, 21, 22].

Although many studies were conducted on the effect of admission hyperglycemia on the short- and long-term outcome of the acute coronary syndrome (ACS) [2, 23–25] unfortunately, there is too scarce available literature about the impact of the glycemic gap on ACS outcome [11].

The main finding in the present prospective study was that the glycemic gap is strongly and significantly related to the occurrence of MACE ($p$ value < 0.001) and longer hospital stay duration ($p$ value < 0.001) in diabetic patients presented to the ED with ACS. These results mimic a retrospective observational study which was conducted by Liao et al. (2016) who enrolled 331 patients to their study, of these patients, 43 (13.0%) died during hospitalization and 61 (18.4%) experienced MACEs and found a relation between elevated glycemic gap and adverse outcomes in diabetic patients presented with acute myocardial infarction. Compared with survivors, non-survivors had a statistically significant higher glycemic gap and longer hospital stay [11].

**Table 3** Agreement (sensitivity, specificity) for admission RBG and glycemic gap value to predict MACE

|                     | AUC   | $P$     | 95% CI   | Cut-off$^a$ | Sensitivity | Specificity | PPV    | NPV    |
|---------------------|-------|---------|----------|-------------|-------------|------------|--------|--------|
| Admission RBG       | 0.500 | 0.994   | 0.384    | > 228       | 94.44       | 21.87      | 40.5   | 87.5   |
| Glycemic gap value  | 0.796$^*$ | < 0.001$^*$ | 0.702 | 0.891 | > 55.876 | 86.11 | 56.25 | 52.5 | 87.8   |

$^a$Cut-off was choose according to Youden index

$^*$Statistically significant at $p \leq 0.05$

*AUC area under a curve, $p$ value probability value, CI confidence intervals, NPV negative predictive value, PPV positive predictive value*
Reviewing previous literature revealed a lot of studies their authors were concerned about finding an association between hyperglycemia and ACS outcome. Capes et al. (2000) found that acute hyperglycemia with myocardial infarction was associated with an increased risk of in-hospital mortality in patients with and without diabetes with increased risk of congestive heart failure or cardiogenic shock in patients without diabetes [5].

K. Foo et al. (2003) studied the relation between a single admission blood glucose value and ACS outcome. They found a marked correlation between hyperglycemia and ACS outcomes. They also found that prognostic correlates of admission glycemia were applied equally to diabetic and non-diabetic subgroups as in both subgroups, the more the hyperglycemia the more the risk of heart failure and cardiac arrest [26]. Sousa et al. (2013) have observed that admission hyperglycemia is an independent predictive factor for in-hospital complications after ACS in diabetic and non-diabetic patients [27].

The risk of acute hyperglycemia was studied by Angeli et al. (2013), and they found that acute hyperglycemia documented during ACS brings an excess risk of mortality not only in the hospital setting [28], but also in the short term (30 days) and long term (up to 108 months). Jacob Lønborg et al. (2014) studied the impact of acute hyperglycemia on myocardial infarct size in patients with STEMI. They concluded that hyperglycemia could serve as a marker for the severity of myocardium at risk and injury [29]. All those studies gave a well-established proof about the association between acute hyperglycemia and adverse outcome after ACS, but no studies highlighted the role and cut-off value of glycemic gap as the current study.

Another point of interest was that many of these studies found no difference regarding the outcome between diabetics and non-diabetics. Some of them even found poor prognosis in non-diabetic patients. This “diabetes paradox” had been continuously observed in other studies with no explanation for that finding except for that there was a hidden factor that was only applied on diabetic patients and not on non-diabetics [3, 30].

Recently, many studies have been concerned about using the glycemic gap in diabetic patients as a predictor for poor outcome in many aspects, e.g., ICU outcomes, community-acquired pneumonia, necrotizing fascitis, acute heart failure, and acute coronary syndrome. All of them related the glycemic gap to adverse outcome and so more hospital stay length but without determining the glycemic gap cut-off value [31–35].

Generally, the stress response is known as an adaptive process for survival which benefits in drastically disturbed physiological situations, such as acute illness. Stress triggers systemic inflammatory response that accompanies secondary complications, such as acute hyperglycemia and insulin resistance. Stress-induced hyperglycemia has a direct correlation with the morbidity and mortality rates in critical illness.

Stress hyperglycemia is the result of sympathetic nervous system activation and the hypothalamic–pituitary axis with subsequent increased production of catecholamine and cortisol levels that stimulate gluconeogenesis, glycogenolysis, and lipolysis. Surprisingly, morbidity and mortality associated with hyperglycemia were especially severe in patients who were not previously diagnosed as diabetics. In diabetic patient with ACS, stress-induced hyperglycemia represents the fraction of hyperglycemia that represents the damage limit on the level of myocardium. Stress-induced hyperglycemia had been reported to be associated with acute adrenergic signal of stress and endothelial cell dysfunction in acute myocardial infarction, which was partially attributed to endothelial cell apoptosis, reactive oxygen species (ROS) over production and inflammation [36–38].

Most of studies which were concerned about the relation between HbA1c and ACS outcomes that were conducted in the past, whether found no relation between them [39–41] or found a relation but on the long term [42, 43]. Very few studies found a relation between glycated hemoglobin and ACS short-term outcomes.

In the current study, it was found that HbA1c measured values were inversely related to MACE occurrence and long hospital stay with a statistically significant relation. Results which were discordant with most of the previously conducted studies except one study conducted by Li et al. (2014), who reported that higher levels of HbA1c were associated with less risk of myocardial injury following PCI in diabetic patients because of better energy supply. As a large number of ACS patients included in the current study had primary PCI (n = 57), this might account for the confounding factor in short-term prognosis [44].

**Limitations**

A number of limitations have influenced the current study. The sample size was relatively small, the study was hospital-based where all participants were of the same ethnicity, and therefore the findings may be not generally applicable to other population. Also, glycemic control during hospitalization was not implied for and correlated to the results.

The study highlighted the complications that occurred during the hospital stay only, which provided us with a short-term follow-up for patients as far as a maximum of 2 weeks. This creates a limitation to the study in giving information about the long-term outcomes.
Case study

A 61-year-old diabetic male patient with history of CCS and smoking with STE-ACS managed by primary PCI. His admission blood glucose is 331 mg/dl, his HbA1c is 8.2 and his glycemic gap measurement is 142 mg/dl. This patient spent 16 days in the hospital (3 ward days and 13 CCU days). During which he witnessed pulmonary edema, ventricular fibrillation and cardiac arrest once.

A 58-year-old diabetic male patient with history of CCS and smoking with STE-ACS managed by primary PCI. His admission blood glucose is 352 mg/dl, his HbA1c is 11.95 and his glycemic gap measurement is 55 mg/dl. This patient’s hospital stay was 4 days (2 CCU days and 2 ward days). He did not witness any complications.

- The two patients have the same age, the same risk factors, the same diagnosis, and the same line of management but they have followed two different outcomes.
- Comparing the RBG in the two cases reveals that the case that witnessed MACE had the lower RBG value of RBG in comparison with case 2.
- Comparing the glycemic gap value in the two cases reveals that the case that witnessed MACE had a higher glycemic gap value in comparison with case 2.

Conclusions

Although many studies stated that glycemic gap could be used as a biomarker for predicting MACE and duration of hospital length in diabetic patients with ACS, and that it is a better marker than admission blood glucose alone in diabetic patient presented with ACS, but our study added the optimal cut-off value of this important biomarker which is a glycemic gap of 55 mg/dl, to predict complications.

Acknowledgements

This work was supported by Internal Medicine Department (Diabetes Unit), Faculty of Medicine, Alexandria University.

Authors’ contributions

All authors contributed to the study conception and design. All authors performed the study equally, contributed to the extraction of data, analyzed the data, wrote the paper, and approved the manuscript. All authors have critically reviewed and approved the final draft.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

All related data and materials are available on proper request.

References

1. Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendic S, Ryderén L et al (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359(9324):2140–2144
2. Shah B, Amoroso NS (2012) Sedlis SP. Aotms. Hyperglycemia in nondiabetic patients presenting with acute myocardial infarction. Am J Med Sci 343(4):321–326
3. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Hegarty C et al (2008) Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 36(8):2249–2255
4. American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes care 37(Supplement 1):S81–90
5. Capes SE, Hunt D, Malmberg K, Gerstein HC. (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Crit Care Med 35(9):773–778
6. Fava S, Aquilina O, Azzopardi J, Muscat HA, Fenech FF. (1996) The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. J Am College Cardiol 13(1):80–83
7. Malmberg K, Ryderén L, Hamsten A, Herlitz J, Waldenström A, Wedel H, et al. (1997) Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. European Soc Cardiol 34(1):248–253
8. Esposito K, Marfella R, Giugliano DJ. (2003) Stress hyperglycemia, inflammation, and cardiovascular events. Am Diabetes Assoc 26(5):1650–1651
9. Marfella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis UJ, Romano C et al (2003) Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Am Diabetes Assoc 26(11):3129–3135
10. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. (2008) Translating the A1C assay into estimated average glucose values. New Engl J Med 359(38):1473–1478
11. Liao W-J, Lin C-S, Lee C-H, Wu Y-C, Chang W-C, Hsu C-W et al (2016) An elevated glycemic gap is associated with adverse outcomes in diabetic patients with acute myocardial infarction. Scientific Rep 6(1):1–11
12. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction): AHA 44(3):671–719
13. Komajda M, Follath F, Ko S, Cieland J, Aguilar J, Cohen-Solal A et al (2003) The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment. AHA 24(5):464–474
14. Marjion E, Luy-Evansado A, Dumas F, Karam N, Reiner K, Teodorescu C et al (2016) Warning symptoms are associated with survival from sudden cardiac arrest. Ann Int Med 164(1):23–29
15. Kumar A, Cannon CP (2009) Acute coronary syndromes: diagnosis and management, part I. In: Mayo Clinic Proceedings, Vol. 84, No. 10. Elsevier, p. 917–38
16. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M et al (2002) Hyperglycemia: an independent marker of in-hospital mortality. J Clin Endocrinol Metab 87(3):978–982
17. Viana MV, Moraes RB, Fabbrin AR, Santos MF, Gerchman F (2014) Admission blood glucose level as risk indicator of death after myocardial infarction. Am J Cardiol 112(9):1306–1310
18. Deckers JW, van Domburg RT, Akkerhuis M, Nauta STJTAjoc. (2013) Relationship of glycated hemoglobin levels with myocardial infarction following elective percutaneous coronary intervention in patients with diabetes. Medicine 94(36).
19. Su G, Mi SH, Li Z, Tao H, Yang HK, HJCd Z (2013) Prognostic value of early in-hospital glycemic excursion in elderly patients with acute myocardial infarction. Cardiovasc Diabetol J 12(1):33
20. Ye Y, Xie H, Zhao X, Zhang SJ D (2012) The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy. Cardiovasc Diabetol 11(1):155
21. Jacobs J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C et al (2003) A single serum glucose measurement predicts adverse outcomes in patients with diabetes. Medicine 94(17).
22. Kowalczyk J, Mazurek T, Zielinska T, Lenarczky R, Sedwicka A, Swiatkowski A et al (2015) Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. SAGE Journal 42(3):798–806
23. Savonitto S, Morico N, Nozza C, Costentino F, Perrone Filardi P, Murena E et al (2018) Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. SAGE Journal 151(1):14–23
24. Østergaard H, Mandrup-Poulsen T, Berkelmans G, van der Graaf Y, Visseren FL et al (2014) Impact of acute hyperglycemia on myocardial infarction undergoing primary angioplasty. Cardiovasc Diabetol J 11(1):155
25. She J, Deng Y, Wu Y, Xia Y, Li H, Liang X et al (2017) Hemoglobin A 1c is associated with severity of coronary artery stenosis but not with long term clinical outcomes in diabetic and nondiabetic patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Diabetol 16(1):97
26. Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, Qing P, Wu NQ, Jiang LX, Xu B, Gao RL (2014) Relationship of glycosylated hemoglobin levels with myocardial injury following elective percutaneous coronary intervention in patients with type 2 diabetes mellitus. PLoS One 9(7):e101719

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.